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Metronidazole-induced encephalopathy in a patient 
with liver cirrhosis
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Encephalopathy is a disorder characterized by altered brain function, which can be attributed to various causes. Encephalopathy 
associated with metronidazole administration occurs rarely and depends on the cumulative metronidazole dose, and most 
patients with this condition recover rapidly after discontinuation of therapy. Because metronidazole is metabolized in the liver and 
can be transported by the cerebrospinal fluid and cross the blood-brain barrier, it may induce encephalopathy even at a low 
cumulative dose in patients with hepatic dysfunction. We experienced a patient who showed ataxic gait and dysarthric speech 
after receiving metronidazole for the treatment of hepatic encephalopathy that was not controlled by the administration of 
lactulose. The patient was diagnosed as metronidazole-induced encephalopathy, and stopping drug administration resulted in a 
complete recovery from encephalopathy. This case shows that caution should be exercised when administering metronidazole 
because even a low dose can induce encephalopathy in patients with liver cirrhosis. (Korean J Hepatol 2011;17:157-160)
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INTRODUCTION
Metronidazole is a 5-nitroimidazole derivative and is used 
clinically to treat Crohn’s disease, abdominal abscess, cellulitis, 
extradural abscess, meningitis, postoperative inflammation, 
and infection with Helicobacter pylori.
1 In addition, it is 
used to treat hepatic encephalopathy that is caused by liver 
cirrhosis but cannot be controlled by administration of 
lactulose.
2 The known adverse effects of the drug include 
peripheral neuropathy, convulsion, encephalopathy, cerebellar 
dysfunction, vertigo, ataxia, and dysarthria.
3 We observed 
dysarthria and ataxia after administration of metronidazole 
in a patient with hepatic encephalopathy that could not be 
controlled by administration of lactulose, and we diagnosed 
the condition as metronidazole-induced encephalopathy on 
the basis of brain magnetic resonance imaging (MRI) 
findings. Drug administration was then stopped, and the 
metronidazole-induced encephalopathy reversibly improved. 
Here, we report a case of metronidazole-induced encephalo-
pathy with a review of the literature. 
 
CASE REPORT
A 57-year-old man visited the hospital for right chest pain 
after falling down in the bathroom. He had been hospitalized 
several times for alcoholic liver cirrhosis with hepatic 
encephalopathy. He has drunk 160 g of alcohol everyday for 
35 years but had abstained from drinking for the previous 11 
months. He had also been taking metronidazole 750 mg/day 
beginning 10 days before admission because his hepatic 
encephalopathy was not controlled by administration of 
lactulose. At admission, his blood pressure was 100/60 
mmHg, body temperature was 36.5℃, pulse rate was 
90/min, and respiratory rate was 20/min. In the physical 
examinations, chronically ill appearance, icteric sclera, 
traces of bruising and some tenderness on the right thoracic 158  The Korean Journal of Hepatology Vol. 17. No. 2, June 2011
  
Figure 1. T2-weighted brain magnetic resonance images showed symmetrically increased signal intensity (arrows) in both the dentate 
nucleus (A) and the splenium of the corpus callosum (B).
  
Figure 2. Five weeks after discontinuation of metronidazole, T2-weighted brain magnetic resonance images showed complete resolution 
of the high signal intensity in both the dentate nucleus (A) and the splenium of the corpus callosum (B).
wall, splenomegaly of the left upper quadrant, and pitting 
edema in the peripheral extremities were observed. Blood 
chemistry tests revealed the following findings: hemoglobin, 
12.6 g/dL; leukocyte count, 5,270/mm
3; platelet count, 
50,000/mm
3; aspartate aminotransferase (AST), 34 IU/L; 
alanine aminotransferase (ALT), 21 IU/L; total bilirubin, 5.7 
mg/dL; prothrombin time, 20.8 s; alkaline phosphatase, 404 
IU/L; and ammonia, 45 μM/L. Rib series and chest computed 
tomography (CT) scans showed multiple rib fractures and 
hemothorax. Therefore, we performed thoracostomy. Dysarthria 
and ataxia occurred on day 25 after thoracostomy (total dose 
of metronidazole, 30 g), and a state of confusion was 
reported on day 26. Subsequently, we performed an arterial 
blood test and an electrolyte test and measured the blood 
ammonia levels. The results of these examinations were 
within normal limits. Brain CT scans showed increased 
density in the corpus callosum. Brain MRI, T2-weighted and 
FLAIR images showed a high signal intensity in the dentate 
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nuclei on both sides and in the splenium of the corpus callosum, 
and the diffusion-weighted images showed vasogenic edematous 
lesions in a part of the corpus callosum. Therefore, metronidazole- 
induced encephalopathy was suspected (Fig. 1). In addition, 
the T1-weighted image showed high signal intensity in the 
superior ganglion on both sides and in the cerebral peduncle, 
suggesting hepatic encephalopathy. The patient was transferred 
to the liver disease clinic, metronidazole was discontinued, 
and conservative treatment for liver cirrhosis and encephalopathy 
was initiated. One day after discontinuation of metronidazole, 
he showed improvement in dysarthria and the state of 
consciousness, and after 2 days, he showed a normal state of 
consciousness. Two weeks after stopping metronidazole 
administration, weakness of the lower extremities reduced. 
In follow-up brain MRI, which was performed after 5 
weeks, we confirmed the disappearance of high signal 
intensity in the superior ganglion on both sides and in the 
splenium of the corpus callosum in T2-weighted and FLAIR 
images (Fig. 2). After 1 month, the patient was able to walk, 
and he is currently under outpatient follow-up. He is also 
receiving lactulose and rifaximin to control the repeated 
episodes of hepatic encephalopathy. 
DISCUSSION
Metronidazole, a drug used for the treatment of various 
abscesses caused by infection with anaerobic bacteria, can 
decrease ammonia production by inhibiting the growth of 
intestinal bacteria. Therefore, it is also used to treat hepatic 
encephalopathy that cannot be controlled by lactulose. The 
common adverse events associated with metronidazole 
treatment are nausea, bad taste, headache, and dizziness, and 
in rare cases, encephalopathy. The occurrence of encephalopathy 
depends on the cumulative dose, and encephalopathy 
presents with sudden symptoms such as cerebellar dysfunction, 
ataxia, dysarthria, convulsion, encephalopathy, and vertigo.
3 
In the Korean medical database, 11 cases of metronidazole- 
induced neuropathy have been reported. In these cases, the 
symptoms appeared after 21 g to 135 g of metronidazole had 
been administered.
4-10 Three of these 11 patients showed 
peripheral neuropathy,
4 while the other 9 showed ence-
phalopathy.
5-10
With regard to its pharmacological action, metronidazole 
shows microbicidal activity against anaerobic bacteria by 
blocking the action of a DNA repair enzyme.
3 Approximately, 
30-60% of metronidazole is metabolized in the liver, and the 
metabolite has antimicrobial activity, passes through the 
cerebrospinal fluid, and crosses the blood-brain barrier.
1 The 
half-life of the drug is 6-8 hours, but in hepatic encephalopathy 
patients, its clearance rate is reduced by one-third because of 
diminished liver function; as a result, the half-life of the drug 
is increased approximately 3-folds in these patients.
11 
Accordingly, in patients with liver cirrhosis, the drug 
accumulates in the blood faster, which raises blood levels 
and causes encephalopathy symptoms such as decreased 
consciousness.
9 Even our patient had liver cirrhosis, he 
experienced cerebellar dysfunction symptoms such as ataxia 
and encephalopathy symptoms such as dysarthria and confusion 
after the administration of a relatively low cumulative dose 
of 30 g. Another study has reported that encephalopathy 
occurred earlier in patients with renal dysfunction (21 g 
administered over a 2-week period).
7 Although previous 
studies have shown that the half-life of metronidazole does 
not increase when hemodialysis is performed,
12 the half-life 
of hydroxyl metabolites is believed to increase, and their 
accumulation leads to encephalopathy at a relatively low 
cumulative dose.
13 Accordingly, it is necessary to limit the 
total cumulative dose to less than 20 g. Furthermore, when 
metronidazole is used, the patient’s neurological symptoms 
should be monitored closely.
Metronidazole-induced encephalopathy may cause sym-
ptoms such as dysarthria, gait disturbance, dizziness, and 
decreased consciousness, and can be accompanied by a 
tingling sensation in the distal extremities. Our patient also 
showed the typical symptoms such as ataxia, dysarthria, and 
confusion, but he did not experience paresthesia in the distal 
extremities. In most cases of metronidazole-induced ence-
phalopathy, including our case, these symptoms disappear 
completely within a few days after discontinuation of 
therapy. However, a recent study reported a case in which 
the patient died of encephalopathy.
11 The patient took 
metronidazole for 10 weeks, and the total cumulative dose 
was 132 g. The drug administration was stopped after symptoms 
of encephalopathy appeared, however, the patient’s symptoms 
did not improve and died 8 weeks after the onset of the 
symptoms. As evidenced by this case, metronidazole- 
induced encephalopathy is not always reversible and may 
result in a fatal outcome. Therefore, when metronidazole is 
administered, the dose and duration of treatment should be 
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Metronidazole-induced encephalopathy can be definitively 
diagnosed if the patient experiences new neurological 
disorders or if brain MRI shows characteristic lesions in a 
patient who is receiving metronidazole.
14 Patients with 
metronidazole-induced encephalopathy typically show 
characteristic symmetric lesions in brain MRI, and such 
lesions are usually limited to the region around the cerebellar 
dentate nuclei. However, some rare cases may also show 
multiple symmetric lesions in the corpus callosum, midbrain, 
pons, white matter, basal ganglia, etc., and high signal 
intensity in T2-weighted, FLAIR, and diffusion-weighted 
images. Since the brain MRI findings of our patient also 
showed a high signal intensity (T2-weighted image) in both 
the dentate nuclei and the corpus callosum, we suspected the 
condition to be metronidazole-induced encephalopathy. The 
high signal intensity seen on T2-weighted brain MRI images 
is believed to appear because the 5-nitroimidazole derivative 
generates toxic radicals via the oxidation of neurotransmitters 
such as catecholamines, and the radicals damage metallic 
ion-containing nerve cells in the brain, thereby increasing 
water content and causing axonal swelling.
15 Low signal 
intensity was rarely observed in apparent diffusion coefficient 
maps. In one such case, cytotoxic edema was caused by a 
mechanism other than cell ischemia and had a poor prognosis.
16 
When MRI shows multiple symmetric lesions in the white 
matter and the gray matter without mass effect, it is necessary 
to differentiate this condition from hypoglycemia, electrolyte 
disturbance, trauma, acute disseminated encephalomyelitis, 
inflammatory disease, diseases that affect the nervous 
system or metabolism, as well as from drug toxicity caused 
by drugs such as anticonvulsants.
15 Among the 10 cases of 
metronidazole-induced encephalopathy reported in Korea, 8 
(including our case) showed characteristic MRI findings 
(high signal intensity in cerebellar dentate nucleus, corpus 
callosum, midbrain, and basal ganglia on T2- weighted 
images); however, the other 2 patients did not show such 
findings, and they were diagnosed on the basis of clinical 
outcomes. In all cases that underwent follow-up MRI, the 
characteristic high signal intensity had disappeared.
Metronidazole-induced encephalopathy is treated with 
discontinuation of drug therapy. After discontinuation of 
drug therapy, most symptoms improve, but occasionally, the 
symptoms of peripheral neuropathy persist in the distal 
extremities.
4
In conclusion, metronidazole is an effective drug for the 
treatment of various abscesses caused by infection with 
anaerobic bacteria and hepatic encephalopathy not controlled 
by administration of lactulose. However, for older patients, 
patients with liver cirrhosis, and patients with renal failure 
who have reduced drug metabolism, it is necessary to restrict 
the total dose and the duration of administration and consider 
the cumulative dose. Caution should be exercised, particularly 
for cases of liver cirrhosis that are similar to our case, 
because hepatic encephalopathy may occur even after low- 
dose metronidazole administration.
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